(Reuters) – GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.
The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology firm includes an upfront payment of 301 million euros and milestone payments of up to 495 million euros.
{iframe}https://www.reuters.com/article/us-gsk-divestiture-bavarian-nordic/gsk-to-sell-two-vaccines-in-1-1-billion-deal-to-focus-on-newer-treatments-idUSKBN1X00NE{/iframe}